Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction?...

Area of Science:

• Cardiology
• Interventional Cardiology
• Diabetology

Background:

• The CAPTIM study compared primary angioplasty versus prehospital fibrinolysis for acute ST-segment elevation myocardial infarction (STEMI) within 6 hours.
• Initial findings showed similar 30-day outcomes for the primary endpoint (death, recurrent MI, stroke) between the two strategies.
• This analysis focuses on the outcomes within the diabetic subgroup of the CAPTIM study.

Purpose of the Study:

• To investigate the treatment outcomes of diabetic patients with acute myocardial infarction (MI) based on reperfusion strategy.
• To compare the effectiveness of primary angioplasty versus prehospital fibrinolysis in diabetic patients presenting with STEMI.

Main Methods:

• Subgroup analysis of the CAPTIM study, comparing diabetic (n=103) and non-diabetic (n=731) patients.
• Patients were randomized to either primary angioplasty or prehospital fibrinolysis (recombinant tissue plasminogen activator, rt-PA).
• Outcomes analyzed included the primary endpoint (death, recurrent MI, stroke) and mortality at 30 days, as well as rates of rescue angioplasty.

Main Results:

• Diabetic patients exhibited a higher baseline risk profile and significantly higher rates of the primary endpoint (14.6% vs. 5.6%, P=0.002) and mortality (8.7% vs. 3.1%, P=0.01) at 30 days compared to non-diabetics.
• In diabetics, prehospital fibrinolysis was associated with a trend towards a higher incidence of the primary endpoint (21.7% vs. 8.8%, P=0.09) and mortality (13.0% vs. 5.3%, P=0.29) compared to primary angioplasty.
• Diabetics had a higher rate of rescue angioplasty (41.4% vs. 23.5%, P=0.01) and significantly higher mortality after rescue angioplasty (17.4% vs. 0%, P=0.001).

Conclusions:

• Diabetic patients with acute myocardial infarction may benefit more from a primary angioplasty strategy.
• The observed trends suggest potential harm from prehospital fibrinolysis in this subgroup.
• Further dedicated studies are needed to confirm these findings due to the limited sample size of the diabetic subgroup.